Nuvation Bio Inc. Class A Common Stock (NUVB)

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment o…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

305

Website

www.nuvationbio.com/

Fundamentals

1-day range

$6.63$7

Market cap

$2.14B

P/E (trailing)

—

P/E (forward)

-444.00

EPS (trailing)

$-0.44

Dividend yield

—

Beta

1.60

Avg. volume

6.82M

Forecasts

10 analyst ratings

Nuvation Bio Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65
• KLRA

  Kailera Therapeutics Inc. Common Stock

  $16.26

  ▼ 12.25%
  Market cap $2.24BP/E —
  $16.19$28.23
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.31BP/E —
  $21.2$56.05
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cantor Fitzgerald Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation
  Fintel · 8/21/2026
• This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
  Benzinga · 8/21/2026
• This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
  Benzinga · 8/21/2026
• This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
  Benzinga · 8/21/2026
• Cantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating
  Benzinga · 8/21/2026
• Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1
  Benzinga · 8/20/2026
• JP Morgan Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation
  Fintel · 8/19/2026
• JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
  Benzinga · 8/18/2026

• Philippe Sauvage · July 15, 2026 · Option Exercise

  1 @ $1.97
• Philippe Sauvage · July 15, 2026 · Option Exercise

  40.0K @ $2.17
• Philippe Sauvage · June 23, 2026 · Option Exercise

  47.7K @ $2.17
• Philippe Sauvage · June 23, 2026 · Sale

  47.7K @ $6.01
• Stacy Markel · June 23, 2026 · Option Exercise

  34.6K @ $1.74
• Stacy Markel · June 23, 2026 · Option Exercise

  90.4K @ $1.87
• Stacy Markel · June 23, 2026 · Sale

  125.0K @ $6.03
• Kerry Wentworth · June 23, 2026 · Option Exercise

  63.0K @ $2.93
• Kerry Wentworth · June 23, 2026 · Sale

  63.0K @ $6.02
• Robert Mashal · June 9, 2026 · Buy

  25.0K @ $4.73
• Robert Mashal · May 21, 2026 · Grant

  123.4K
• Robert B. Bazemore · May 21, 2026 · Grant

  123.4K
• Cui Xiangmin · May 21, 2026 · Grant

  123.4K
• VERNON W ANTHONY · May 21, 2026 · Grant

  123.4K
• BLICKENSTAFF KIM D · May 21, 2026 · Grant

  123.4K

Institutional Ownership

March 31, 2026

Total shares held

217.14M

Total value held

$894.03M

Institutional holders

224